SPOTLIGHT -
Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.
The Exciting Future of Advanced Renal Cell Carcinoma Management
A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.
Unmet Needs in Advanced Renal Cell Carcinoma Management
Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.
Renal Cell Carcinoma: Future Directions in Care
Closing out their discussion on renal cell carcinoma management, experts highlight unmet needs and look toward the future treatment landscape.
Treatment Strategies for Patients Who Progress on Adjuvant Pembrolizumab
Following the advent of adjuvant pembrolizumab in high-risk renal cell carcinoma, experts consider treatment strategies for patients who progress on adjuvant pembrolizumab.
Is Adjuvant Pembrolizumab Standard of Care in Patients at Risk of Recurrence?
Considerations for whether adjuvant pembrolizumab is the new standard of care for patients with renal cell carcinoma at intermediate or high risk of recurrence.
Patient Profile 3: RCC Treated With Adjuvant Pembrolizumab Postnephrectomy
Expert panelists review a clinical scenario of renal cell carcinoma managed with adjuvant pembrolizumab postnephrectomy based on results of the KEYNOTE-564 trial.
Unmet Needs in the Front-Line Setting for Renal Cell Carcinoma
A look at the current unmet needs in front-line renal cell carcinoma treatment.
Patient Quality of Life on Lenvatinib plus Pembrolizumab Treatment for Renal Cell Carcinoma
Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.
Dosing Lenvatinib for Treatment of Advanced Renal Cell Carcinoma
Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.
Dosing Lenvatinib for First-Line Renal Cell Carcinoma Treatment
An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.
Treating Favorable Risk Patients with Renal Cell Carcinoma with Lenvatinib
Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.
Risk Factors in the Management of Advanced Renal Cell Carcinoma
Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.
Novel Combination Strategies in the Treatment of Renal Cell Carcinoma
Before closing out their discussion on intermediate-risk RCC, experts review frontline triplet combinations and possible treatment options following relapse after nivolumab-ipilimumab.
Optimizing RCC Management: Addressing Quality-of-Life Measures and Metastasis
Comprehensive discussion on how to best treat patients with renal cell carcinoma and brain or bone metastasis.
Discontinuing IO/IO Therapy in Intermediate-Risk Renal Cell Carcinoma
Shared insight on the adverse event profile of immunotherapy combination regimens in renal cell carcinoma, including advice on when it is appropriate to discontinue therapy.
Patient Profile 2: Intermediate-Risk RCC Treated With Ipilimumab + Nivolumab
Expert perspectives on the clinical scenario of a patient with intermediate-risk renal cell carcinoma, who is managed with the immunotherapy combination of ipilimumab and nivolumab.
Choosing a Combination Treatment for Advanced Renal Cell Carcinoma
A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.
Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma
Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.
Second-Line Therapy Following a TKI/IO Regimen for Favorable-Risk RCC
A brief discussion on available treatment options after patients progress following frontline TKI/IO therapy with favorable-risk renal cell carcinoma.
Favorable-Risk RCC: AE Management and Dosing With TKI/IO Therapy
A comprehensive review of the adverse event profiles of TKI/IO regimens used in favorable-risk renal cell carcinoma and how these can be managed with dose adjustment.
Choosing Appropriate Patients and Dosing for Lenvatinib + Pembrolizumab in RCC
Expert insights on selecting the appropriate patients and dose for treatment with the lenvatinib plus pembrolizumab regimen in patients with renal cell carcinoma.
Patient Profile 1: Favorable-Risk RCC Treated With Lenvatinib + Pembrolizumab
Experts open their discussion on RCC by reviewing the clinical scenario of a patient with favorable-risk disease who is treated with the TKI/IO regimen of lenvatinib and pembrolizumab.
Impressions of Data and Results from the CLEAR Trial
Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.
Background: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”
Robert J. Motzer, MD, on Main HRQOL Takeaways From Phase 3 CLEAR Trial
Motzer discussed time to deterioration end points for patients with advanced renal cell carcinoma treated with pembrolizumab and lenvatinib in the first-line setting.
Future Use of Novel Combinations for Metastatic RCC Treatment
Drs Toni Choueiri and Robert J. Motzer highlight various strategies with novel-based therapies being explored to address limitations surrounding the treatment of metastatic renal cell carcinoma.
Risk Scoring Systems for Metastatic RCC
Considerations regarding the value of using the IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) criteria to risk-stratify patients with metastatic renal cell carcinoma as novel therapies become more widely used.
Implications for Treating Metastatic RCC With TKI/I-O Regimens Upfront
Recommendations regarding how to use novel combinations such as lenvatinib and everolimus, or lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.
Metastatic RCC: Frontline TKI/IO Safety Data
Treatment-related adverse events to be mindful of when treating patients with metastatic renal cell carcinoma with a TKI/IO regimen, such as lenvatinib and pembrolizumab, in the frontline setting.